Joseph Moscato
Chief Executive Officer bij GENEREX BIOTECHNOLOGY CORPORATION
Profiel
Joseph Moscato is currently the Chairman, President & Chief Executive Officer at Generex Biotechnology Corp.
and the Chairman & Chief Executive Officer at NuGenerex Immuno-Oncology, Inc. He was previously a Principal at Seahawk Capital Corp.
Actieve functies van Joseph Moscato
| Bedrijven | Functie | Begin |
|---|---|---|
| GENEREX BIOTECHNOLOGY CORPORATION | Chief Executive Officer | 21-11-2017 |
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Chief Executive Officer | 01-01-2017 |
Eerdere bekende functies van Joseph Moscato
| Bedrijven | Functie | Einde |
|---|---|---|
Seahawk Capital Corp.
 Seahawk Capital Corp. Food: Specialty/CandyConsumer Non-Durables Seahawk Capital Corp. provides food processing and distribution services. The company is based in Cherry Hill, NJ. | Corporate Officer/Principal | 15-12-2011 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Generex Biotechnology Corp.
 Generex Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Generex Biotechnology Corp. is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. It builds new kind of healthcare company, which provides support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care. The company was founded by Rose C. Perri on September 4, 1997 and is headquartered in Miramar, FL. | Health Technology |
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
Seahawk Capital Corp.
Seahawk Capital Corp. Food: Specialty/CandyConsumer Non-Durables Seahawk Capital Corp. provides food processing and distribution services. The company is based in Cherry Hill, NJ. | Consumer Non-Durables |
